- Home
- JFU vs MIRA Comparison
JFU vs MIRA Comparison
Compare JFU & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- MIRA
- Stock Information
- Founded
- JFU 2006
- MIRA 2020
- Country
- JFU China
- MIRA United States
- Employees
- JFU N/A
- MIRA N/A
- Industry
- JFU Finance: Consumer Services
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- MIRA Health Care
- Exchange
- JFU Nasdaq
- MIRA Nasdaq
- Market Cap
- JFU 17.8M
- MIRA 16.6M
- IPO Year
- JFU 2019
- MIRA 2023
- Fundamental
- Price
- JFU $1.45
- MIRA $1.18
- Analyst Decision
- JFU
- MIRA Strong Buy
- Analyst Count
- JFU 0
- MIRA 2
- Target Price
- JFU N/A
- MIRA $14.00
- AVG Volume (30 Days)
- JFU 6.6K
- MIRA 337.8K
- Earning Date
- JFU 12-09-2022
- MIRA 05-12-2025
- Dividend Yield
- JFU N/A
- MIRA N/A
- EPS Growth
- JFU N/A
- MIRA N/A
- EPS
- JFU 0.09
- MIRA N/A
- Revenue
- JFU $40,614,155.00
- MIRA N/A
- Revenue This Year
- JFU N/A
- MIRA N/A
- Revenue Next Year
- JFU N/A
- MIRA N/A
- P/E Ratio
- JFU $14.70
- MIRA N/A
- Revenue Growth
- JFU N/A
- MIRA N/A
- 52 Week Low
- JFU $1.13
- MIRA $0.51
- 52 Week High
- JFU $3.75
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- JFU 46.78
- MIRA 58.02
- Support Level
- JFU $1.37
- MIRA $0.90
- Resistance Level
- JFU $1.56
- MIRA $1.33
- Average True Range (ATR)
- JFU 0.09
- MIRA 0.12
- MACD
- JFU -0.01
- MIRA 0.03
- Stochastic Oscillator
- JFU 30.77
- MIRA 71.97
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.